The Mitsubishi Pharma Group changed its name to The Tanabe Pharma Group on 1st December 2025. All affiliates that previously bore the Mitsubishi Tanabe name changed their names accordingly to remove the Mitsubishi name.
The Tanabe Pharma Group engages Healthcare Professionals (HCPs) and Healthcare Organisations (HCOs) across Europe.
In accordance with the EFPIA Code of Transfers of Value from Pharmaceutical Companies 2019, details of Transfers of Value made to HCPs and HCOs in Europe by the Tanabe Pharma Group can be found below.
The methodology applied in preparing and collating this data is available here in English*, French* and German*. test
If you are a Healthcare Professional and have any questions regarding the figures disclosed, please contact:
finance.EU@mb.tanabe-pharma.com.
2025 Transfers of Value
AUSTRIA |
| Research & Development | EUR 17,314.84 |
| Non-Research & Development | EUR 49,353.36 |
| Patient Organisation & Advisory Groups | EUR 0.00 |
| Full details here |
BELGIUM |
| Research & Development | EUR 13,844.39 |
| Non-Research & Development | EUR 0.00 |
| Patient Organisation & Advisory Groups | EUR 8,000.00 |
| Full details here |
BULGARIA |
| Research & Development | BGN 13,201.08 |
| Non-Research & Development | BGN 0.00 |
| Patient Organisation & Advisory Groups | BGN 0.00 |
| Full details here |
CROATIA |
| Research & Development | EUR 0.00 |
| Non-Research & Development | EUR 0.00 |
| Patient Organisation & Advisory Groups | EUR 0.00 |
| Full details here |
CYPRUS |
| Research & Development | EUR 0.00 |
| Non-Research & Development | EUR 0.00 |
| Patient Organisation & Advisory Groups | EUR 0.00 |
| Full details here |
CZECH REPUBLIC |
| Research & Development | CZK 291,733.89 |
| Non-Research & Development | CZK 0.00 |
| Patient Organisation & Advisory Groups | CZK 0.00 |
| Full details here |
DENMARK |
| Research & Development | EUR 3,300.41 |
| Non-Research & Development | EUR 0.00 |
| Patient Organisation & Advisory Groups | EUR 0.00 |
| Full details here |
ESTONIA |
| Research & Development | EUR 0.00 |
| Non-Research & Development | EUR 0.00 |
| Patient Organisation & Advisory Groups | EUR 0.00 |
| Full details here |
FINLAND |
| Research & Development | EUR 0.00 |
| Non-Research & Development | EUR 0.00 |
| Patient Organisation & Advisory Groups | EUR 0.00 |
| Full details here |
FRANCE |
| Research & Development | EUR 8,689.76 |
| Non-Research & Development | EUR 0.00 |
| Patient Organisation & Advisory Groups | EUR 0.00 |
| Full details here |
GERMANY |
| Research & Development | EUR 3,891.75 |
| Non-Research & Development | EUR 35,355.16 |
| Patient Organisation & Advisory Groups | EUR 0.00 |
| Full details here |
GREECE |
| Research & Development | EUR 0.00 |
| Non-Research & Development | EUR 0.00 |
| Patient Organisation & Advisory Groups | EUR 0.00 |
| Full details here |
HUNGARY |
| Research & Development | HUF 0.00 |
| Non-Research & Development | HUF 0.00 |
| Patient Organisation & Advisory Groups | HUF 0.00 |
| Full details here |
IRELAND |
| Research & Development | EUR 0.00 |
| Non-Research & Development | EUR 0.00 |
| Patient Organisation & Advisory Groups | EUR 0.00 |
| Full details here |
ITALY |
| Research & Development | EUR 351,768.42 |
| Non-Research & Development | EUR 9,441.00 |
| Patient Organisation & Advisory Groups | EUR 0.00 |
| Full details here |
LATVIA |
| Research & Development | EUR 0.00 |
| Non-Research & Development | EUR 0.00 |
| Patient Organisation & Advisory Groups | EUR 0.00 |
| Full details here |
LITHUANIA |
| Research & Development | EUR 0.00 |
| Non-Research & Development | EUR 0.00 |
| Patient Organisation & Advisory Groups | EUR 0.00 |
| Full details here |
MALTA |
| Research & Development | EUR 0.00 |
| Non-Research & Development | EUR 0.00 |
| Patient Organisation & Advisory Groups | EUR 0.00 |
| Full details here |
THE NETHERLANDS |
| Research & Development | EUR 254,116.01 |
| Non-Research & Development | EUR 0.00 |
| Patient Organisation & Advisory Groups | EUR 0.00 |
| Full details here |
NORWAY |
| Research & Development | NOK 60,813.56 |
| Non-Research & Development | NOK 0.00 |
| Patient Organisation & Advisory Groups | NOK 0.00 |
| Full details here |
POLAND |
| Research & Development | PLN 781,645.20 |
| Non-Research & Development | PLN 0.00 |
| Patient Organisation & Advisory Groups | PLN 0.00 |
| Full details here |
PORTUGAL |
| Research & Development | EUR 24,796.99 |
| Non-Research & Development | EUR 0.00 |
| Patient Organisation & Advisory Groups | EUR 0.00 |
| Full details here |
ROMANIA |
| Research & Development | EUR 0.00 |
| Non-Research & Development | EUR 0.00 |
| Patient Organisation & Advisory Groups | EUR 0.00 |
| Full details here |
RUSSIA |
| Research & Development | RUB 0.00 |
| Non-Research & Development | RUB 0.00 |
| Patient Organisation & Advisory Groups | RUB 0.00 |
| Full details here |
SERBIA |
| Research & Development | EUR 0.00 |
| Non-Research & Development | EUR 0.00 |
| Patient Organisation & Advisory Groups | EUR 0.00 |
| Full details here |
SLOVAKIA |
| Research & Development | EUR 10,088.79 |
| Non-Research & Development | EUR 0.00 |
| Patient Organisation & Advisory Groups | EUR 0.00 |
| Full details here |
SLOVENIA |
| Research & Development | EUR 0.00 |
| Non-Research & Development | EUR 0.00 |
| Patient Organisation & Advisory Groups | EUR 0.00 |
| Full details here |
SPAIN |
| Research & Development | EUR 76,107.30 |
| Non-Research & Development | EUR 1,600.00 |
| Patient Organisation & Advisory Groups | EUR 0.00 |
| Full details here |
SWEDEN |
| Research & Development | SEK 119,042.28 |
| Non-Research & Development | SEK 0.00 |
| Patient Organisation & Advisory Groups | SEK 162,405.00 |
| Full details here |
SWITZERLAND |
| Research & Development | CHF 0.00 |
| Non-Research & Development | CHF 60,377.08 |
| Patient Organisation & Advisory Groups | CHF 0.00 |
| Full details here |
TURKEY |
| Research & Development | EUR 0.00 |
| Non-Research & Development | EUR 0.00 |
| Patient Organisation & Advisory Groups | EUR 0.00 |
| Full details here |
UKRAINE |
| Research & Development | EUR 0.00 |
| Non-Research & Development | EUR 0.00 |
| Patient Organisation & Advisory Groups | EUR 0.00 |
| Full details here |
* The Tanabe Pharma Group has established legal entities in the United Kingdom, Germany and Switzerland and therefore disclosure is made according to local requirements for these countries
